Enhertu head-to-head trial meets primary endpoint
9 August 2021 07:00 BST Enhertu significantly improved progression-free survival in DESTINY-Breast03head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer IDMC recommended unblinding based on primary efficacy endpoint demonstrating superiority; results also indicate strong trend toward improved overall survival Plans for global regulatory submissions underway Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo